How AdAlta’s FDA-Aligned Strategy Accelerates Cell Therapy Breakthroughs

• New FDA manufacturing guidelines support scalable, automated cell therapy production
• First milestone payment of US$0.5 million made to Shanghai Cell Therapy Group
• Additional A$0.15 million Research and Development Tax Incentive refund received
• FDA’s flexible requirements expected to reduce costs and accelerate clinical development